Arabian American Development Co. (NASDAQ: ARSD) Company announced that its subsidiary, South Hampton Resources has signed two new contracts. A five year contract with a North America based company and a three year contract with an international based organization were signed for a total value of more than $29 million over the length of the contracts.
Stock has been on an uptrend rising from $2.80 to presently
$4.76 since November of 2010. Volume has been light, but the company has been
able to continously deliver in its pps performance and keep the bears away. If
you look at the six month chart, you'll see that it has been trending and
bouncing off of its 50-day moving average of $4.09.
Arabian American Development Company is engaged manufacturing various specialty petrochemical products and owning an interest in a Saudi Arabian joint stock mining company and in mineral properties in the United States. The Company's United States activities are primarily conducted through a wholly owned subsidiary, American Shield Refining Company (the Petrochemical Company), which owns of Texas Oil and Chemical Co. II, Inc.
RTI Biologics Inc. (NASDAQ: RTIX) has
reported its Q4 earnings of $0.05 per share, which was in line with the Thomson
Reuters consensus of $0.05. Its revenues rose 8.1% a year to $45.4 mln vs the
$44.8 mln consensus. Company issued downside guidance for Q1, sees EPS of $0.02
vs. $0.03 Thomson Reuters consensus; sees Q1 revs of $38-39 vs. $40.02 mln
Thomson Reuters consensus. Company also issued downside guidance for FY11, sees
EPS of $0.11-0.13 vs. $0.15 Thomson Reuters consensus; sees FY11 revs of
$159-162 vs. $169.15 mln Thomson Reuters consensus.
This stock's pps is in danger as the stock fell through its 50-day moving average of $2.68. This usually means trouble as bears start to sharpen their teeth. What makes it even worse is that the 200-day moving average is still above the 50-day moving average. RTIX has lost 0.76% so far to settle at $2.60 with a moderate volume of 129.8K
RTI Biologics Inc. (RTI) process human and animal tissue.
The Company uses natural tissues and technologies to produce orthopedic and
other surgical implants that repair and promote the natural healing of human
bone and other human tissues. RTI processes human musculoskeletal and other
tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium,
sclera and dermal tissue into allografts, and bovine animal tissue into
xenografts, utilizing BIOCLEANSE and TUTOPLAST sterilization processes, for
distribution to hospitals and surgeons.
Zanett Inc. (NASDAQ: ZANE) Company announced that it has recently signed a 3-year banking relationship with PNC Bank. The 3-year Line of Credit is for a maximum amount of $10 million and initially carries an interest rate of Prime +1.25%. Zanett's original banker was LaSalle Bank, who specialized in helping small and mid-sized business grow steadily year after year. Then LaSalle Bank was purchased by Bank of America. Sometime after the acquisition, and possibly in part due to the credit crisis, Bank of America informed Zanett that they were no longer servicing the segment of the market to which Zanett belonged, thus renewing the Bank of America relationship was not feasible.
ZANE is an interesting play as the stock skyrocketed yesterday
33% and has been relatively good in hanging on to its gains. There was a lot of
profit taking today as the stock dropped 5.7% to settle at $1.47 with a strong
volume of $291,721.
Zanett Inc. (Zanett) is an information technology company that provides customized IT solutions to Fortune 500 corporations and mid-market companies. The Company provides commercial solutions through its wholly owned subsidiaries. The Company's subsidiaries include Zanett Commercial Solutions, Inc., Data Road, Inc. and PS GoLive, LLC.
Myrexis, Inc. (NASDAQ: MYRX) Updated
pre-clinical and clinical data including two completed Phase 2 studies of Azixa
in combination with standard chemotherapies for the treatment of brain tumors
were highlighted in the December 2010 edition of Drugs of the Future by lead
investigator Lawrence Recht, M.D., Department of Neurology, Stanford University
School of Medicine.
This one is depicting a perfect bullish 50-day and 200-day crossover on top of the stock breaking its 50-day moving average of $3.98. Stock rose almost a 1% to settle at $4.13 with a moderate volume of 17K. Moving Aver. Conv. Diverg. is also about to cross, so keep an eye out on that as well when you trade this security.
Myrexis, Inc. (Myrexis) is a biotechnology company focused on discovering, developing and commercializing treatments for cancer. The Company's development pipeline includes clinical and pre-clinical product candidates. Myrexis retains all rights to all of its drug candidates and programs across all geographic markets and therapeutic indications. As of June30, 2010, the Company had two clinical-stage programs in oncology: Azixa and MPC-3100. In June 2010, Myrexis announced the suspension of its human immunodeficiency virus (HIV) maturation inhibitor programs.
Generex Biotechnolog Corporation
(NASDAQ: GNBT) Company announced that together with
its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc.,
that Antigen Express has received a Notice of Allowance from the United States
Patent Office relating to an application making augmentative pharmaceutical
composition claims for the Antigen Express AE37 immunotherapeutic cancer
vaccine. The company has previously received allowances of broad claims
surrounding its Ii-Key hybrid technology, which was used in the design of the
AE37 vaccine platform. The current allowance strengthens independent
composition of matter claims directed to the AE37 peptide. The full term of the
new patent will extend through January 5, 2028.
GNBT has been in trouble for a while now as the stock
tumbled upon touching its every resistance point of 50-day moving average of
$0.32 and then again $0.29. Now it sold off 0.40% to settle at $0.23. I would
keep this on a watch list just because its been oversold and could pop a few
percentage points in a short period of time.
Generex Biotechnology Corporation is a development-stage company. The Company is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses at the technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes
"forward-looking statements" within the meaning of the federal
securities laws, commonly identified by such terms as "believes,"
"looking ahead," "anticipates," "estimates" and
other terms with similar meaning. Although the Company believes that the
assumptions upon which its forward-looking statements are based are reasonable,
it can give no assurance that these assumptions will prove to be correct.
Important factors that could cause actual results to differ materially from the
Company's projections and expectations are disclosed in the Company's filings
with the Securities and Exchange Commission. All forward-looking
statements in this press release are expressly qualified by such cautionary
statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any stocks listed in this stock news report
